A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

Summary

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. It will also assess how the new vaccine works in comparison to the one that is currently in use when given with other childhood vaccines.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Pneumococcal Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

42 to 211 days

Sex

All

Healthy volunteers

Accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

September 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites